SG11201602019XA - Multigene assay for prognosis of renal cancer - Google Patents

Multigene assay for prognosis of renal cancer

Info

Publication number
SG11201602019XA
SG11201602019XA SG11201602019XA SG11201602019XA SG11201602019XA SG 11201602019X A SG11201602019X A SG 11201602019XA SG 11201602019X A SG11201602019X A SG 11201602019XA SG 11201602019X A SG11201602019X A SG 11201602019XA SG 11201602019X A SG11201602019X A SG 11201602019XA
Authority
SG
Singapore
Prior art keywords
prognosis
renal cancer
multigene assay
multigene
assay
Prior art date
Application number
SG11201602019XA
Inventor
Min-Han Tan
Yukti Choudhury
Puay Hoon Tan
Bin Tean Teh
Original Assignee
Agency Science Tech & Res
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Singapore Health Serv Pte Ltd filed Critical Agency Science Tech & Res
Priority to SG11201602019XA priority Critical patent/SG11201602019XA/en
Publication of SG11201602019XA publication Critical patent/SG11201602019XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1072Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes
SG11201602019XA 2013-09-17 2014-09-17 Multigene assay for prognosis of renal cancer SG11201602019XA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201602019XA SG11201602019XA (en) 2013-09-17 2014-09-17 Multigene assay for prognosis of renal cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2013070149 2013-09-17
PCT/SG2014/000446 WO2015050500A1 (en) 2013-09-17 2014-09-17 Multigene assay for prognosis of renal cancer
SG11201602019XA SG11201602019XA (en) 2013-09-17 2014-09-17 Multigene assay for prognosis of renal cancer

Publications (1)

Publication Number Publication Date
SG11201602019XA true SG11201602019XA (en) 2016-04-28

Family

ID=52778982

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602019XA SG11201602019XA (en) 2013-09-17 2014-09-17 Multigene assay for prognosis of renal cancer

Country Status (4)

Country Link
US (1) US11015190B2 (en)
EP (1) EP3047040B1 (en)
SG (1) SG11201602019XA (en)
WO (1) WO2015050500A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127805A1 (en) * 2016-03-15 2019-05-02 Almac Diagnostics Limited Gene signatures for cancer detection and treatment
JP2019518970A (en) * 2016-04-08 2019-07-04 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック Methods and kits for predicting sensitivity to cancer treatment of subjects suffering from kidney cancer
KR102350603B1 (en) * 2019-04-03 2022-01-14 고려대학교 산학협력단 Composition for diagnosing or prognosing cancer including exosome based tuba1c proteins
CN113430266A (en) * 2021-06-25 2021-09-24 复旦大学附属肿瘤医院 Application of G6PC and genome thereof in preparation of renal clear cell carcinoma diagnosis or prognosis evaluation system
CN113444794B (en) * 2021-06-25 2023-01-06 复旦大学附属肿瘤医院 Application of combined genome in preparation of renal clear cell carcinoma prognosis evaluation system
WO2023276869A1 (en) * 2021-06-28 2023-01-05 学校法人 久留米大学 Method for predicting prognosis after treatment with angiogenesis inhibitor, and combination therapy for cancer
EP4361288A1 (en) * 2022-10-25 2024-05-01 Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) Personalized immunotherapy in renal carcinoma
CN117187375A (en) * 2023-09-12 2023-12-08 上海谱希和光基因科技有限公司 Application of KDELR3 biomarker in diagnosis of high myopia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
RU2010123381A (en) * 2007-11-09 2011-12-20 Дженентек, Инк. (Us) METHOD AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
WO2010083252A2 (en) * 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2011062634A2 (en) 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
JP6286124B2 (en) * 2010-01-11 2018-02-28 ジェノミック ヘルス, インコーポレイテッド A method to determine the likelihood of clinical outcome of renal cancer using gene expression

Also Published As

Publication number Publication date
EP3047040A1 (en) 2016-07-27
US20160230234A1 (en) 2016-08-11
EP3047040B1 (en) 2019-12-11
US11015190B2 (en) 2021-05-25
EP3047040A4 (en) 2017-07-12
WO2015050500A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
IL285521A (en) Assays for single molecule detection
HK1217218A1 (en) Biomarkers for colorectal cancer
HK1219763A1 (en) Compositions and methods for cancer prognosis
IL289514A (en) Assays for determining plasma kallikrein system biomarkers
EP2825674A4 (en) Thyroid cancer biomarker
SG11201602019XA (en) Multigene assay for prognosis of renal cancer
EP3004374A4 (en) Affinity-based detection of ligand-encoded synthetic biomarkers
DK3435084T3 (en) PROSTATE CANCER PROGNOSIS USING BIOMARKERS
PL2726635T3 (en) Multigene prognostic assay for lung cancer
EP2951592A4 (en) Autoantibody signature for the early detection of ovarian cancer
EP2982985A4 (en) System for predicting prognosis of locally advanced gastric cancer
IL276505B (en) Predicting breast cancer recurrence
DK2914739T3 (en) COMBINATIONS OF BIOMARKERS FOR COLORECTAL TUMORS
EP2986326A4 (en) Methods for detecting cancer metastasis
HK1213634A1 (en) Methods of detecting cancer
EP2977760A4 (en) Biomarker for diagnosing liver cancer
EP3058101A4 (en) Serum mirnas for the prognosis of prostate cancer
HK1224010A1 (en) Biomarkers for ovarian cancer
EP3047277A4 (en) Autoantibody biomarkers of ovarian cancer
EP2972376A4 (en) Methods for determining prognosis of colorectal cancer
EP3047039A4 (en) Inhibiting cancer metastasis
EP3015476A4 (en) Tumor biomarker
GB201306339D0 (en) Biomarkers for prognosis
EP3060914A4 (en) Methods of determining breast cancer prognosis
EP3077549A4 (en) Gene signatures for renal cancer prognosis